News

Filter

Current filters:

Aromasin

1 to 9 of 36 results

Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer

10-12-2010

Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased…

ArimidexAromasinAstraZenecaFemaraNovartisOncologyPfizerPharmaceuticalResearch

Pfizer’s Aromasin little different to tamoxifen in disease progression for breast cancer patients

14-12-2009

Global pharmaceutical behemoth Pfizer announced disappointing results at the San Antonio Breast Cancer…

AromasinExemestaneNorth AmericaOncologyPfizerPharmaceutical

Pfizer's Aromasin boosts DFS 11% in early breast cancer

22-12-2008

Pfizer's aromatase inhibitor Aromasin (exemestane) given to women with early breast cancer reduces the…

AromasinExemestanePfizer

St Gallen guidelines recommend switch from tamoxifen to an AI for HER2 breast cancer

13-08-2007

A consensus report issued by the world's leading breast cancer experts has confirmed the value of switching…

AnastrozoleArimidexAromasinAstraZenecaExemestaneFemaraLetrozoleNovartisPfizer

Pfizer's Aromasin cuts endometiral thickening in breast cancer

11-06-2007

USA-based drug major Pfizer says that data from a study examining its steroidal aromatase inhibitor Aromasin…

AromasinExemestanePfizer

Pfizer data indicates differences between steroidal and non-steroidal aromatase inhibitors

26-03-2007

In a presentation at the 10th International Conference on Adjuvant Therapy of Primary Breast Cancer in…

AromasinExemestaneFaslodexFulvestrantPfizer

1 to 9 of 36 results

COMPANY SPOTLIGHT

Menarini

Back to top